These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa. Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193 [No Abstract] [Full Text] [Related]
8. Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment. Atzori L; Bonato F; Pilloni L; Rongioletti F Dermatol Ther; 2020 Jan; 33(1):e13160. PubMed ID: 31705612 [TBL] [Abstract][Full Text] [Related]
9. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective. Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056 [TBL] [Abstract][Full Text] [Related]
10. Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa. Patil S Indian J Dermatol Venereol Leprol; 2018; 84(6):745-747. PubMed ID: 30289113 [No Abstract] [Full Text] [Related]
11. Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient. Molina-Leyva A; Badiola J AIDS; 2018 Oct; 32(16):2436-2438. PubMed ID: 30281563 [No Abstract] [Full Text] [Related]
12. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study. Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335 [TBL] [Abstract][Full Text] [Related]
13. Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction. Company-Quiroga J; Alique-García S; Martínez-Morán C; Khedaoui R; Romero-Maté A; Borbujo J Indian J Dermatol Venereol Leprol; 2019; 85(4):422-425. PubMed ID: 31115357 [No Abstract] [Full Text] [Related]
15. Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa. Sugaya M; Ishii M; Takahashi-Shishido N; Ichimura Y; Morimura S J Dermatol; 2021 Apr; 48(4):e163-e164. PubMed ID: 33502014 [No Abstract] [Full Text] [Related]
16. New onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab. Phan K; Charlton O; Smith SD Dermatol Ther; 2020 May; 33(3):e13347. PubMed ID: 32239739 [No Abstract] [Full Text] [Related]
17. Long-term efficacy and safety of adalimumab on a severe case of hidradenitis suppurativa. Caposiena Caro RD; Cannizzaro MV; DI Raimondo C; DI Matteo E; Botti E; Rossi P; Bianchi L Ital J Dermatol Venerol; 2021 Feb; 156(1):101-102. PubMed ID: 30350561 [No Abstract] [Full Text] [Related]
18. Wells syndrome in a patient receiving adalimumab biosimilar: A case report and review of literature. Dabas G; De D; Handa S; Chatterjee D; Radotra BD Indian J Dermatol Venereol Leprol; 2018; 84(5):594-599. PubMed ID: 30058563 [No Abstract] [Full Text] [Related]
19. Adalimumab-Induced Neutropenia in a Man With Hidradenitis Suppurativa. Rueda Carnero JM; Nieto Rodríguez D; de Lucas Laguna R; Feito Rodríguez M Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):273-274. PubMed ID: 31980127 [No Abstract] [Full Text] [Related]
20. Candida Esophagitis Associated With Adalimumab for Hidradenitis Suppurativa. Nazarian RS; Farberg AS; Smith BL Cutis; 2021 Mar; 107(3):E6-E7. PubMed ID: 33956612 [No Abstract] [Full Text] [Related] [Next] [New Search]